Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Si Jun Zi Tang in Perioperative NSCLC
NCT06445881Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of modified sijunzi decoction in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: R0 Resection Rate, Objective Response Rate at 6 weeks and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
modified sijunzi decoction
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06445881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445881.